Dozens of states sue to block the sale of 23andMe personal genetic data
Summary
Twenty-seven states and Washington, D.C., filed a lawsuit to stop the sale of 23andMe's personal genetic data without customer consent. This lawsuit follows 23andMe's bankruptcy and a drug company's plan to buy it for $256 million.Key Facts
- Twenty-seven states and Washington, D.C., filed a lawsuit in bankruptcy court.
- The lawsuit aims to stop 23andMe from selling personal genetic data without customer consent.
- 23andMe is a company that uses saliva kits to provide ancestry and health information.
- The company has faced financial difficulties and filed for bankruptcy protection.
- Regeneron Pharmaceuticals wants to buy 23andMe for $256 million.
- Regeneron claims it will honor existing privacy policies and laws regarding personal data.
- A court-appointed ombudsman will review the privacy impact of the sale.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
